U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic for sarcoma biopsy market
The growing prevalence of osteosarcoma is expanding the size of the global sarcoma biopsy market. Osteosarcoma is the most common type of cancer affecting bones. According to the American Cancer Society, IN January 2020, around 800 to 900 new cases of osteosarcoma are diagnosed in the U.S. each year, with around 50% occurs in children and teenagers. Also, the advent of an advanced diagnostic test for diagnosing cancer is again expected to foster the growth of the sarcoma biopsy market. Needle biopsy and surgical biopsy are the fastest-growing segments in the sarcoma biopsy market. North America is expected to hold a dominant position in the global sarcoma biopsy market due to increasing healthcare expenditure in the U.S. For instance, according to the Committee for a Responsible Federal Budget, in 2017, the U.S. spent around the US $ 3.5 trillion, or 18% of the total GDP, on health expenditures, which is more than twice the average among developed countries. In January 2020,...